Background
Methods
Downloading the data files
Grouping studies for analysis using RankProd software
DAVID analysis
Results
Datasets characterization
Sr. No | Acc. No. | Platform | Set | S+R | S cell lines | R Cell lines | Cell Type | Pretreatment | Inhibitor |
---|---|---|---|---|---|---|---|---|---|
1 | GSE34228 | Agilent-014850 | 1 | 26+26 | PC9 | PC9GR | Non-Small Cell Lung Cancer | No | Gefitinib |
2 | 26+26 | PC9 | PC9GR | Non-Small Cell Lung Cancer | EGF | Gefitinib | |||
3 | 26+26 | PC9 | PC9GR | Non-Small Cell Lung Cancer | IRS | Gefitinib | |||
4 | 26+26 | PC9 | PC9GR | Non-Small Cell Lung Cancer | EGF+IRS | Gefitinib | |||
2 | GSE10696 | Affy HG_ U133_Plus_2.0 | 1 | 3+3 | A431 | A431GR | A431 cancer cell line | No | Gefitinib |
3 | GSE38310 | Illumina HumanHT-12 V3.0 | 1 | 3+3 | HCC827 | T15-2 | Non-Small Cell Lung Cancer | DMSO | Erlotinib |
2 | 3+3 | HCC827 | T15-3 | Non-Small Cell Lung Cancer | Erlotinib | Erlotinib | |||
3 | 3+3 | HCC827 | ER-3 | Non-Small Cell Lung Cancer | DMSO | Erlotinib | |||
4 | 3+3 | HCC827 | ER-3 | Non-Small Cell Lung Cancer | Erlotinib | Erlotinib | |||
4 | GSE40130 | Illumina HumanWG-6 v3.0 | 1 | 2+3 | HN5 | FADU | Head and Neck cancer cell lines | No | Erlotinib |
Illumina HumanHT-12 V4.0 | 2 | 2+3 | HN5 | FADU | Head and Neck cancer cell lines | miR-7 | Erlotinib | ||
5 | GSE49135 | Illumina HumanHT-12 V4.0 | 1 | 3+3 | HN5 | HN5ER | Head and Neck cancer cell lines | No | Erlotinib |
6 | GSE37699 | Affy_HG_U133A_2 | 1 | 3+3 | NSCLC | NCl-H1975 | Non-Small Cell Lung Cancer | No | WZ4002 |
7 | GSE38404 | Affy_HG_U133A_2 | 1 | 2+6 | NSCLC | PFR31, PFR32 | Non-Small Cell Lung Cancer | No | PF299804 |
8 | GSE21483 | Affy HG_ U133_Plus_2.0 | 1 | 3+3 | SCC1 | 1Cc8 | Skin cancer cell line | No | Cetuximab |
Total | 15 | 274 |
Global comparison of all EGFR inhibitors-sensitive vs. resistant cell lines
All studies: Overexpressed in sensitive cells | Overexpressed in resistant cells | ||||
---|---|---|---|---|---|
Term | p-value | Term | p-value | ||
Table 2a
| |||||
O
| Pathways in cancer | 4.9E-15 |
T
| positive regulation of biosynthetic process | 3.6E-17 |
MM
| plasma membrane part | 7.7E-12 |
T
| positive regulation of cellular biosynthetic process | 5.2E-17 |
CC
| regulation of cell proliferation | 1.3E-10 |
T
| positive regulation of macromolecule Metabolic process | 2.3E-16 |
MM
| endomembrane system | 1.4E-10 |
R
| response to endogenous stimulus | 8.9E-16 |
MM
| cell fraction | 2.1E-09 |
T
| positive regulation of nitrogen compound Metabolic process | 1.6E-15 |
A
| regulation of cell death | 2.2E-09 |
T
| positive regulation of macromolecule biosynthetic process | 9.3E-15 |
A
| regulation of programmed cell death | 2.6E-09 |
CC
| regulation of cell proliferation | 4.9E-14 |
Mt
| positive regulation of macromolecule Metabolic process | 2.6E-09 |
R
| response to hormone stimulus | 6.9E-14 |
CC
| cell proliferation | 5.7E-09 |
R
| response to organic substance | 9.6E-14 |
T
| protein complex biogenesis | 7.0E-09 |
CC
| positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid Metabolic process | 1.2E-13 |
Table 2b
| |||||
A
| negative regulation of cell death | 1.4E-07 |
A
| regulation of apoptosis | 3.3E-10 |
AD
| cell migration | 5.0E-08 |
A
| negative regulation of apoptosis | 4.1E-10 |
AD
| cell adhesion | 2.3E-07 |
A
| anti-apoptosis | 8.1E-08 |
AD
| localization of cell | 1.2E-06 |
CC
| cell cycle | 8.2E-06 |
AD
| cell projection | 3.2E-06 |
CC
| regulation of cell size | 3.4E-05 |
AD
| Focal adhesion | 4.3E-05 |
CY
| cytoskeletal protein binding | 3.2E-06 |
CC
| negative regulation of cell proliferation | 9.0E-05 |
CY
| actin cytoskeleton | 1.0E-04 |
CC
| regulation of DNA Metabolic process | 1.5E-04 |
DF
| negative regulation of cell differentiation | 6.1E-06 |
CC
| mitotic cell cycle | 5.9E-04 |
E
| regulation of oxidoreductase activity | 5.1E-05 |
CC
| regulation of cell size | 6.4E-04 |
E
| positive regulation of oxidoreductase activity | 4.2E-04 |
IM
| response to wounding | 4.4E-05 |
IM
| immune system development | 1.8E-09 |
IM
| immune system development | 6.2E-04 |
IM
| response to wounding | 2.4E-08 |
IM
| T cell activation | 6.8E-04 |
IM
| regulation of cytokine production | 1.1E-07 |
IM
| humoral immune response | 8.4E-04 |
IM
| positive regulation of immune system process | 4.3E-06 |
M_c
| oligosaccharide Metabolic process | 7.0E-04 |
IM
| positive regulation of cell activation | 2.6E-05 |
M_l
| regulation of lipid Metabolic process | 6.8E-06 |
IM
| inflammatory response | 2.8E-05 |
M_l
| phosphoinositide Metabolic process | 7.3E-05 |
IM
| wound healing | 1.6E-04 |
M_l
| positive regulation of lipid Metabolic process | 1.0E-04 |
IM
| immune response | 1.8E-04 |
M_l
| lipid biosynthetic process | 1.1E-04 |
IM
| defense response | 4.5E-04 |
M_l
| phospholipid Metabolic process | 2.3E-04 |
IM
| regulation of production of molecular mediator of immune response | 9.1E-04 |
M_l
| cellular lipid catabolic process | 4.2E-04 |
M_c
| monosaccharide Metabolic process | 4.3E-06 |
M_l
| glycerolipid Metabolic process | 5.4E-04 |
M_c
| hexose Metabolic process | 1.2E-05 |
M_l
| glycerophospholipid Metabolic process | 7.0E-04 |
M_c
| glucose Metabolic process | 5.8E-05 |
M_l
| lipoprotein particle clearance | 9.2E-04 |
M_c
| regulation of cellular ketone Metabolic process | 2.0E-04 |
O
| Oncogenesis | 3.4E-05 |
M_l
| regulation of lipid Metabolic process | 2.6E-07 |
O
| ErbB signaling pathway | 4.2E-04 |
M_l
| regulation of lipid biosynthetic process | 1.1E-04 |
O
| Wnt signaling pathway | 7.7E-04 |
M_l
| regulation of fatty acid Metabolic process | 4.2E-04 |
M_l
| positive regulation of lipid Metabolic process | 4.9E-04 | |||
Legend:
|
MO
| regulation of cell motion | 2.8E-12 | ||
A
| Apoptosis |
O
| Pathways in cancer | 2.8E-10 | |
AD
| Adhesion |
O
| regulation of DNA Metabolic process | 1.2E-04 | |
CC
| Cell cycle |
O
| Ras protein signal transduction | 2.1E-04 | |
CY
| Cytoskeleton |
O
| Oncogenesis | 4.0E-04 | |
DF
| Differentiation |
R
| response to steroid hormone stimulus | 6.2E-12 | |
E
| Energy |
R
| response to insulin stimulus | 1.5E-07 | |
Mt
| Metabolism |
R
| response to vitamin | 1.2E-06 | |
IM
| Immunity |
R
| response to lipopolysaccharide | 1.8E-06 | |
M_c
| Metabolism-carbohydrates |
R
| response to glucocorticoid stimulus | 2.6E-06 | |
M_l
| Metabolism-lipids |
R
| response to hydrogen peroxide | 1.4E-05 | |
MM
| Membrane |
R
| cellular response to stress | 3.1E-05 | |
MO
| Motility |
V
| regulation of angiogenesis | 4.6E-06 | |
O
| Oncogenesis |
V
| myeloid leukocyte activation | 4.4E-05 | |
R
| Response to stimuli |
V
| positive regulation of angiogenesis | 4.2E-04 | |
T
| Transcription/translation | ||||
V
| Vasculogenesis | ||||
Sensitive
|
Resistant
| ||||
Table 2c
| |||||
ErbB Signalling pathway
|
Ras protein signal transduction
| ||||
BCL2-associated agonist of cell death | v-ral oncogene homolog A | ||||
mitogen-activated protein kinase 9 | FERM, RhoGEF and pleckstrin domain | ||||
phosphoinositide-3-kinase beta | nischarin | ||||
glycogen synthase kinase 3 beta | IGF1 (somatomedin C) | ||||
c-abl oncogene 1 | Rho GTPase activating protein 6 | ||||
v-crk sarcoma virus CT10 | X-associated ankyrin-containing protein | ||||
mitogen-activated protein kinase 8 | ras homolog gene family, member A | ||||
ribosomal protein S6 kinase | myosin IXB | ||||
mitogen-activated protein kinase 10 | mitogen-activated protein kinase 1 | ||||
phosphoinositide-3-kinase alpha | GRB2-related adaptor protein 2 | ||||
phospholipase C, gamma 1 | Rho GTPase activating protein 5 | ||||
CDK inhibitor 1A (p21, Cip1) | soc-2 suppressor of clear homolog | ||||
epiregulin | mitogen-activated protein kinase 14 | ||||
v-myc oncogene homolog | ropporin, rhophilin associated protein 1B | ||||
phosphoinositide-3-kinase subunit 5 | r-ras oncogene homolog | ||||
v-erb-b2 oncogene homolog 2 | CDC42 effector protein | ||||
v-aktoncogene homolog 1 | fibroblast growth factor 2 (basic) | ||||
calcium/calmodulin-dep. protein kinase II | G protein alpha 12 | ||||
protein kinase C, alpha | parathyroid hormone | ||||
neuregulin 1 | GRB2-related adaptor protein | ||||
NCK adaptor protein 1 | muscle RAS oncogene homolog | ||||
PTK2 protein tyrosine kinase 2 | WAS protein family, member 2 | ||||
phosphoinositide-3-kinase delta | SHC transforming protein 1 | ||||
betacellulin | MAPKAP 2 | ||||
ribosomal protein S6 kinase 2 | Rho guanine nucleotide exchange factor 3 | ||||
jun oncogene | ATP-binding cassette, member 1 | ||||
p21 (Cdc42/Rac)-activated kinase 2 | cofilin 1 (non-muscle) | ||||
translation initiation factor 4E binding | CDC42 effector protein 4 | ||||
phospholipase C, gamma 2 | neurofibromin 1 | ||||
neurotrophic tyrosine kinase, type 1 | |||||
ral GDF stimulator-like 2 | |||||
linker for activation of T cells | |||||
Sensitive
|
Resistant
| ||||
Table 2d
| |||||
Complement System
| |||||
complement component 2 | complement component 1, q A chain | ||||
complement component 3a receptor 1 | complement component 1, q B chain | ||||
complement component 7 | complement factor H | ||||
complement component 8, alpha | |||||
complement component 8, beta | |||||
complement component 9 | |||||
complement factor B | |||||
complement factor H | |||||
complement factor I | |||||
Chemokines
| |||||
chemokine (C-C motif) ligand 2 | chemokine (C-C motif) ligand 13 | ||||
chemokine (C-C motif) ligand 22 | chemokine (C-C motif) ligand 19 | ||||
chemokine (C-C motif) ligand 23 | chemokine (C-C motif) ligand 2 | ||||
chemokine (C-C motif) ligand 24 | chemokine (C-C motif) ligand 20 | ||||
chemokine (C-C motif) receptor 5 | chemokine (C-C motif) ligand 8 | ||||
chemokine (C-C motif) receptor 5 | |||||
chemokine (C-X-C motif) ligand 1 | |||||
chemokine (C-X-C motif) ligand 13 | |||||
chemokine (C-X-C motif) ligand 6 | |||||
Interleukins
| |||||
interleukin 1, alpha | interleukin 1 family, member 6 | ||||
interleukin 10 | interleukin 1, alpha | ||||
interleukin 2 receptor, alpha | interleukin 1, beta | ||||
interleukin 6 (interferon, beta 2) | interleukin 10 | ||||
interleukin 8 | interleukin 10 receptor, beta | ||||
interleukin 13 | |||||
interleukin 22 | |||||
interleukin 5 | |||||
interleukin 6 (interferon, beta 2) | |||||
interleukin 9 |
Comparison of Erlotinib-sensitive vs. resistant cell lines
Erlotinib: Overexpressed in sensitive cells | Overexpressed in resistant cells | ||||
---|---|---|---|---|---|
Term | p_value | Term | p_value | ||
Table 3a
| |||||
T
| translation | 5.6E-62 | cytosol | 3.0E-20 | |
T
| translational elongation | 6.3E-45 |
T
| translational elongation | 3.1E-18 |
T
| structural constituent of ribosome | 1.0E-43 |
T
| structural constituent of ribosome | 3.4E-18 |
cytosol | 3.7E-41 |
T
| ribosomal subunit | 3.5E-17 | |
T
| ribosome | 4.5E-41 |
T
| cytosolic ribosome | 2.4E-16 |
T
| 3' -UTR-mediated translational regulation | 3.8E-40 |
E
| mitochondrion | 1.5E-15 |
T
| ribonucleoprotein complex | 5.0E-40 |
T
| Ribosome | 2.6E-14 |
T
| Ribosome | 4.6E-37 |
T
| ribosome | 2.6E-14 |
T
| ribosomal subunit | 9.9E-36 |
IM
| Influenza Infection | 4.2E-14 |
T
| Protein biosynthesis | 2.0E-33 |
CY
| intracellular non-membrane-bounded organelle | 8.2E-13 |
Table 3b
| |||||
CC
| Cell cycle | 1.8E-04 |
CC
| mitotic cell cycle | 3.2E-08 |
E
| mitochondrion | 2.4E-10 |
CC
| M phase of mitotic cell cycle | 9.1E-06 |
E
| intramolecular oxidoreductase activity | 4.4E-04 |
CY
| actin cytoskeleton | 5.3E-06 |
M_c
| glycolysis | 2.1E-07 |
E
| mitochondrial inner membrane | 7.1E-12 |
M_c
| Metabolism of carbohydrates | 3.3E-06 |
E
| mitochondrial envelope | 7.2E-12 |
M_c
| carbohydrate catabolic process | 7.5E-05 |
E
| oxidative phosphorylation | 1.5E-10 |
M_c
| Glycolysis / Gluconeogenesis | 1.7E-04 |
E
| hydrogen ion transmembrane transporter activity | 1.8E-10 |
M_c
| glucose metabolic process | 6.4E-04 |
E
| generation of precursor metabolites and energy | 3.4E-10 |
T
| Metabolism of proteins | 5.4E-29 |
E
| Oxidoreductase | 6.6E-10 |
T
| ribosome biogenesis | 6.6E-21 |
E
| Dehydrogenase | 3.9E-09 |
T
| ncRNA metabolic process | 4.7E-19 |
E
| Integration of energy metabolism | 1.6E-06 |
T
| mitochondrial ribosome | 4.0E-05 |
E
| electron transport chain | 1.8E-05 |
E
| mitochondrial lumen | 1.9E-04 | |||
E
| mitochondrial matrix | 1.9E-04 | |||
E
| NADH dehydrogenase (ubiquinone) activity | 2.3E-04 | |||
E
| mitochondrial ATP synthesis coupled electron transport | 2.8E-04 | |||
T
| Metabolism of proteins | 2.7E-09 | |||
T
| Protein biosynthesis | 1.6E-07 | |||
T
| Gene Expression | 1.5E-06 |
Comparison of Gefitinib-sensitive vs. resistant cell lines
Gefitinib: Overexpressed in sensitive cells | Overexpressed in resistant cells | ||||
---|---|---|---|---|---|
Term | p_value | Term | p_value | ||
Table 4a
| |||||
O
| Pathways in cancer | 6.8E-14 |
T
| positive regulation of biosynthetic process | 1.7E-11 |
O
| Pancreatic cancer | 1.2E-07 |
T
| positive regulation of macromolecule metabolic process | 3.1E-11 |
T
| protein complex assembly | 3.7E-06 |
T
| positive regulation of cellular biosynthetic process | 3.5E-11 |
T
| protein complex biogenesis | 3.7E-06 |
T
| positive regulation of nitrogen compound metabolic process | 1.6E-10 |
CC
| regulation of cell proliferation | 3.9E-06 |
T
| positive regulation of macromolecule biosynthetic process | 4.4E-10 |
O
| Bladder cancer | 7.8E-06 |
R
| response to endogenous stimulus | 5.1E-10 |
S
| regulation of protein kinase cascade | 8.7E-06 |
CC
| positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | 3.6E-09 |
AD
| cell adhesion | 9.0E-06 |
R
| response to hormone stimulus | 8.1E-09 |
AD
| biological adhesion | 9.8E-06 |
O
| Pathways in cancer | 1.0E-08 |
T
| positive regulation of macromolecule metabolic process | 1.0E-05 |
T
| positive regulation of transcription | 1.5E-08 |
Table 4b
| |||||
A
| regulation of cell death | 3.6E-05 |
A
| negative regulation of programmed cell death | 1.0E-06 |
A
| negative regulation of cell death | 4.4E-05 |
CC
| regulation of cell proliferation | 3.5E-08 |
A
| regulation of apoptosis | 7.9E-05 |
CC
| positive regulation of cell proliferation | 1.9E-06 |
CC
| cell proliferation | 1.6E-05 |
CC
| cell cycle | 2.7E-04 |
M_l
| regulation of lipid metabolic process | 3.1E-05 |
CY
| cytoskeleton organization | 5.3E-06 |
M_l
| positive regulation of lipid metabolic process | 3.4E-04 |
CY
| cell morphogenesis | 2.0E-04 |
O
| ErbB signaling pathway | 5.2E-04 |
E
| regulation of oxidoreductase activity | 4.9E-04 |
HY
| response to hypoxia | 8.7E-06 | |||
HY
| response to reactive oxygen species | 2.4E-04 | |||
HY
| response to hydrogen peroxide | 6.3E-04 | |||
IM
| immune system development | 4.1E-07 | |||
IM
| regulation of cytokine production | 9.2E-07 | |||
IM
| regulation of cytokine biosynthetic process | 2.8E-06 | |||
IM
| response to wounding | 7.3E-05 | |||
IM
| positive regulation of cytokine biosynthetic process | 1.1E-04 | |||
IM
| Signaling in Immune system | 1.3E-04 | |||
M_c
| glucose metabolic process | 5.1E-04 | |||
M_l
| regulation of lipid metabolic process | 2.9E-04 | |||
R
| response to steroid hormone stimulus | 4.5E-08 | |||
R
| response to nutrient levels | 3.6E-07 | |||
R
| response to extracellular stimulus | 6.8E-07 | |||
R
| response to drug | 2.5E-06 | |||
R
| response to nutrient | 3.7E-05 | |||
R
| response to vitamin | 3.7E-05 | |||
R
| response to corticosteroid stimulus | 4.3E-05 | |||
R
| response to glucocorticoid stimulus | 9.1E-05 | |||
R
| response to lipopolysaccharide | 1.7E-04 | |||
R
| response to abiotic stimulus | 3.4E-04 | |||
R
| negative regulation of response to external stimulus | 6.8E-04 | |||
V
| hemopoiesis | 1.2E-07 | |||
V
| leukocyte differentiation | 9.4E-06 | |||
V
| blood circulation | 4.9E-05 | |||
V
| circulatory system process | 4.9E-05 | |||
V
| lymphocyte differentiation | 7.4E-05 | |||
V
| regulation of angiogenesis | 1.1E-04 | |||
V
| blood vessel development | 1.2E-04 | |||
V
| vasculature development | 1.8E-04 |
Comparison of sensitive vs. resistant cell lines obtained using irreversible EGFR inhibitors
Irreversible: Overexpression in sensitive cells | Overexpression in resistant cells | ||||
---|---|---|---|---|---|
Term | p_value | Term | p_value | ||
Table 5a
| |||||
MM
| endomembrane system | 3.8E-09 |
EC
| extracellular region | 1.6E-08 |
MM
| Golgi apparatus | 2.4E-07 | ectoderm development | 3.3E-07 | |
MM
| cell fraction | 1.0E-05 |
IM
| response to wounding | 4.3E-07 |
CC
| cell division | 2.1E-05 |
EC
| extracellular region part | 1.3E-06 |
MM
| organelle membrane | 3.1E-05 |
EC
| extracellular space | 2.4E-06 |
MM
| nuclear envelope-endoplasmic reticulum network | 5.9E-05 | epidermis development | 8.4E-06 | |
R
| response to organic substance | 8.1E-05 |
CC
| regulation of cell proliferation | 1.1E-05 |
MM
| endoplasmic reticulum membrane | 1.0E-04 |
CC
| regulation of smooth muscle cell proliferation | 6.5E-05 |
CC
| Mitosis | 1.1E-04 |
IM
| wound healing | 7.3E-05 |
MM
| 1p22.1 | 1.5E-04 |
CC
| positive regulation of smooth muscle cell proliferation | 1.9E-04 |
Table 5b
| |||||
CC
| cell cycle | 3.1E-04 |
IM
| defense response | 5.9E-04 |
M_l
| steroid metabolic process | 4.3E-04 |
IM
| inflammatory response | 9.2E-04 |
O
| epidermal growth factor receptor binding | 2.5E-04 | |||
O
| ErbB signaling pathway | 4.2E-04 | |||
Genes overexpressed in resistant cells
| |||||
Table 5c
| |||||
EGFR Binding ligands
|
ErbB sig pathway
| ||||
amphiregulin; amphiregulin B | Cas-Br-M ecotropic retroviral transforming sequence c | ||||
epidermal growth factor receptor | amphiregulin; amphiregulin B | ||||
Epiregulin | epidermal growth factor receptor | ||||
heparin-binding EGF-like growth factor | epiregulin | ||||
heparin-binding EGF-like growth factor | |||||
transforming growth factor, alpha | |||||
v-erb-b2 oncogene homolog 3 |
Comparison of Cetuximab-sensitive vs. resistant cell lines
Cetuximab: Overexpressed in sensitive cells | Overexpressed in resistant cells | ||||
---|---|---|---|---|---|
Term | p_value | Term | p_value | ||
Table 6a
| |||||
IM
| response to wounding | 1.3E-10 |
DF
| ectoderm development | 9.2E-10 |
CC
| regulation of cell proliferation | 1.6E-09 |
DF
| epidermis development | 1.4E-09 |
CC
| positive regulation of cell proliferation | 3.5E-07 |
DF
| epithelium development | 1.0E-08 |
M
| chemotaxis | 8.9E-07 |
DF
| epithelial cell differentiation | 1.5E-07 |
M
| taxis | 8.9E-07 |
DF
| keratinocyte differentiation | 6.2E-05 |
M
| cell migration | 1.7E-06 |
DF
| cornified envelope | 6.5E-05 |
M
| localization of cell | 2.6E-06 |
EC
| extracellular matrix | 7.8E-05 |
M
| cell motility | 2.6E-06 |
DF
| epidermal cell differentiation | 1.2E-04 |
M
| Cell communication | 3.5E-06 |
DF
| peptide cross-linking | 1.7E-04 |
R
| regulation of response to external stimulus | 4.0E-06 |
IM
| wound healing | 1.7E-04 |
Table 6b
| |||||
IM
| inflammatory response | 6.5E-06 |
CC
| regulation of cell proliferation | 4.3E-04 |
IM
| wound healing | 9.1E-06 |
CY
| Cell structure and motility | 3.3E-04 |
IM
| immune response | 9.8E-06 |
CY
| 12q12-q13 | 6.9E-04 |
IM
| Immunity and defense | 6.7E-05 |
T
| transcription repressor activity | 8.4E-04 |
IM
| regulation of inflammatory response | 3.5E-04 | |||
S
| Signal transduction | 1.5E-05 | |||
S
| Jak-STAT signaling pathway | 5.1E-04 | |||
S
| JAK-STAT cascade | 6.7E-04 | |||
V
| regulation of vascular endothelial growth factor production | 3.2E-05 | |||
V
| Angiogenesis | 3.8E-05 | |||
V
| blood coagulation | 5.8E-04 |